Innovent Biologics, Inc. (HKG:1801)
84.60
-1.50 (-1.74%)
Oct 28, 2025, 4:08 PM HKT
Innovent Biologics Revenue
Innovent Biologics had revenue of 5.95B CNY in the half year ending June 30, 2025, with 120.36% growth. This brings the company's revenue in the last twelve months to 11.42B, up 53.18% year-over-year. In the year 2024, Innovent Biologics had annual revenue of 9.42B with 51.82% growth.
Revenue (ttm)
11.42B CNY
Revenue Growth
+53.18%
P/S Ratio
11.58
Revenue / Employee
2.02M CNY
Employees
5,659
Market Cap
144.96B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.42B | 3.22B | 51.82% |
| Dec 31, 2023 | 6.21B | 1.65B | 36.21% |
| Dec 31, 2022 | 4.56B | 286.65M | 6.71% |
| Dec 31, 2021 | 4.27B | 425.91M | 11.08% |
| Dec 31, 2020 | 3.84B | 2.80B | 266.94% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| JD Health International | 71.34B |
| BeOne Medicines AG | 35.81B |
| Sino Biopharmaceutical | 33.49B |
| Alibaba Health Information Technology | 32.81B |
| CSPC Pharmaceutical Group | 28.49B |
| WuXi Biologics | 21.98B |
| Hansoh Pharmaceutical Group Company | 14.45B |
| WuXi XDC Cayman | 5.58B |
Innovent Biologics News
- 1 day ago - China's Innovent says its GLP-1 works better than Novo's semaglutide in diabetes study - Reuters
- 1 day ago - Innovent's Mazdutide Shows Superiority in Glycemic Control with Weight Loss over Semaglutide in a Head-to-head Phase 3 Clinical Trial DREAMS-3 - PRNewsWire
- 5 days ago - Market Today: Innovent and Takeda's $11.4B Deal Boosts Biotech Sector - GuruFocus
- 6 days ago - Innovent Biologics (IVBIY) and Takeda Partner for $11.4 Billion Cancer Therapy Deal - GuruFocus
- 6 days ago - Innovent inks $11.4 billion cancer drug partnership with Japan's Takeda - Seeking Alpha
- 6 days ago - China's Innovent Strikes Cancer Drug Deal With Takeda for Up to $11.4 Billion - WSJ
- 6 days ago - Takeda And Innovent Biologics Sign Global Oncology Collaboration Outside Greater China - Nasdaq
- 6 days ago - China's Innovent signs $11.4 billion cancer therapy deal with Japan's Takeda - Reuters